Research map: Toward a CKLM framework for integrated clinical trial design

Back to the article

Papers in this map

  1. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review · Zobair M. Younossi · 2023 · 3310 citations · Cited by this paper
  2. Post-transplant CKLM: extending integrated clinical trial design to solid organ transplant recipients · Alessandro Mattina · 2026 · Cites this paper
  3. A patient-driven agenda for liver cirrhosis research · 2026 · Related
  4. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association · Chiadi E. Ndumele · 2023 · 1330 citations · Cited by this paper
  5. International consensus on intestinal epithelial barrier assessment and therapeutic effects in inflammatory bowel diseases clinical trials · 2026 · Related
  6. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications · Giovanni Targher · 2024 · 882 citations · Cited by this paper
  7. Large language models for detecting colorectal polyps in endoscopic images—further research is required · 2026 · Related
  8. Metabolic dysfunction-associated steatotic liver disease in adults · Daniel Q. Huang · 2025 · 286 citations · Cited by this paper
  9. USP20 promotes CD8 + T cell exhaustion and impairs KRAS G12D inhibitor efficacy by orchestrating cholesterol metabolism and autophagy in pancreatic cancer · 2026 · Related
  10. The role of hepatokines in NAFLD · Norbert Stefan · 2023 · 285 citations · Cited by this paper
  11. Galectin-14, a primate-specific oncofetal protein, impairs anti-tumour immunity in hepatocellular carcinoma by driving elevated heparan sulphate modification · 2026 · Related
  12. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials · Ellen M. Apperloo · 2024 · 156 citations · Cited by this paper
  13. Cancer neuroscience in cholangiocarcinoma: from perineural invasion to neuroimmune control · 2026 · Related
  14. Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periostin · Wei Xie · 2024 · 55 citations · Cited by this paper
  15. Cryptogenic steatotic liver disease: a lean phenotype associated with increased liver-related mortality · 2026 · Related
  16. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines · Chiadi E. Ndumele · 2026 · 35 citations · Cited by this paper
  17. Safety and efficacy of extended surveillance intervals following colorectal endoscopic submucosal dissection: an international multicentre study · 2026 · Related
  18. MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials · Faiez M. Zannad · 2024 · 32 citations · Cited by this paper
  19. Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease · Luis Antonio Díaz · 2025 · 26 citations · Cited by this paper
  20. Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management · Xiaodong Zhou · 2026 · 26 citations · Cited by this paper
  21. MASLD, MASH, and the CKM Spectrum · Faïez Zannad · 2026 · 25 citations · Cited by this paper
  22. Cardiovascular–kidney–metabolic syndrome and MASLD: integrating medical perspectives · Xiaodong Zhou · 2025 · 23 citations · Cited by this paper
  23. Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities · Xiao-Dong Zhou · 2025 · 22 citations · Cited by this paper
  24. MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome · Xiaodong Zhou · 2026 · 15 citations · Cited by this paper
  25. Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease · Nicola Riccardo Pugliese · 2026 · 3 citations · Cited by this paper
  26. Metabolic Liver Disease Beyond the Liver · Amalia Gastaldelli · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)